Search - tctmd.com

Displaying 801 - 820 of 879

Sort: Relevancy | Date

News Conference News TCT 2012

New Results from SYNTAX, SPIRIT Trials Presented

October 22, 2012

News Conference News TCT 2012

Meta-Analyses Show Improved Outcomes with DES vs. BMS

October 22, 2012

Presentation TCT 2012

J-DESSERT: A Prospective, Randomized Trial of Paclitaxel-Eluting vs. Sirolimus-Eluting Stents in Patients with and without Diabetes

Presenter: Masato Nakamura

October 22, 2012

Presentation TCT 2012

Final Data on the ICARUS Trial of Covered Stents for Obstructive Iliac Disease

Presenter: John Laird Jr

October 22, 2012

Presentation TCT 2012

Dedicated Bifurcation Stents: Xience SBA Program Update

Presenter: David Rizik

October 22, 2012

Presentation TCT 2012

Dedicated Bifurcation Stents: STENTYS Program Update

Presenter: Stefan Verheye

October 22, 2012

Presentation TCT 2012

Debate I. Are Drug-Eluting Stents Now the Default Strategy for SFA Intervention? - Con!

Presenter: Lawrence Garcia

October 22, 2012

News Conference News TCT 2012

COURAGE, FAME: Revascularization More Effective Than OMT

October 22, 2012

Presentation TCT 2012

ACE-CTO: Angiographic Follow-up After Everolimus-eluting Stents in CTO

Presenter: Emmanouil Brilakis

October 22, 2012

Presentation TCT 2012

Use Of Paclitaxel-Eluting Stents Reduces Target Lesion Revascularization for Dialysis Patients.

Presenter: Hirotoshi Watanabe, Kyohei Yamaji, Yoshimitsu Soga, Shinichi Shirai, Kenji Ando, Koyu Sakai, Katsuhiro Kondo, Masashi Iwabuchi, Hiroyoshi Yokoi, Hideyuki Nosaka, Masakiyo Nobuyoshi

January 03, 2012

Presentation TCT 2012

Two-Year Outcomes of a Propensity-Matched Comparison of the ION and TAXUS Liberté Paclitaxel-Eluting Stents.

Presenter: Dean J. Kereiakes, Louis A. Cannon, John A. Ormiston, Hong Wang, Paul L. Underwood, Keith D. Dawkins

January 03, 2012

Presentation TCT 2012

Twelve-Month Clinical Efficacy and Safety of Zotarolimus- versus Everolimus-Eluting Stents in a Series of Asian Population

Presenter: SunWon Kim, Seung Woon Rha, Byoung Geol Choi, Amro Elnagar, Sung Il Im, Jin Oh Na, Seong Woo Han, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh

January 03, 2012

Presentation TCT 2012

Tissue coverage and neointimal hyperplasia of overlap vs. non-overlap segments in drug-eluting stents 9-13 months after implantation: in vivo-assessment with optical coherence...

Presenter: Juan Luis Guti?rrez-Chico, Lorenz R?ber, Evelyn Regar, Takayuki Okamura, Carlo di Mario, Stephan Windecker, Gerrit-Anne van Es, Patrick W. Serruys

January 03, 2012

Presentation TCT 2012

The Nine-Month Outcomes of a Polymer-Free Drug-Eluting Stent (YUKON) Compared with Different Polymer Based Drug-Eluting Stents in Real-World Coronary Artery Lesions.

Presenter: Ted S. Trajceski, Lulzim Brovina, Zivko Petrovski, Blerim Zuna, Borce Petrovski

January 03, 2012

Presentation TCT 2012

The Impact of XIENCE V® Everolimus-Eluting Coronary Stents on Health Status in COURAGE-Like Patients.

Presenter: David R. Rutledge, James B. Hermiller, Jin Wang, Mitchell W. Krucoff

January 03, 2012

Presentation TCT 2012

Short-term effects of sirolimus eluting fully bioabsorbable polymeric coronary stents in a porcine model

Presenter: Li Shen, Qibing Wang, Yizhe Wu, Jian Xie, Junbo Ge

January 03, 2012

Presentation TCT 2012

Safety and Efficacy of the Xience Everolimus Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice.

Presenter: Israel M. Barbash, Rebecca Torgusson, Itsik Ben-Dor, Gabriel Maluenda, Zhenyi Xue, William O. Suddath, Lowell F. Satler, Kenneth M. Kent, Augusto D. Pichard, Ron Waksman

January 03, 2012

Presentation TCT 2012

Safety and Effectiveness of Everolimus-Eluting Stents in 5054 Patients from a Large, Prospective, Real World Study: Two-Year Clinical Outcomes from the XIENCE V® USA Study.

Presenter: Mitchell W. Krucoff, David R. Rutledge, Vivian W. Mao, Weiying Zhao, Alena V. Pechonkina, Jin Wang, Lalitha K. Jonnavithula, Krishnankutty Sudhir, James B. Hermiller

January 03, 2012

Presentation TCT 2012

Response of Endothelial Progenitor Cells To Antiproliferative Drugs Currently Used in Drug Eluting Stents

Presenter: Hao Xu, Kytai T. Nguyen, Lance S. Terada, Eric Fuh, Joseph A. Garcia, Emmanouil S. Brilakis, Deepak L. Bhatt, Subhash Banerjee

January 03, 2012

Presentation TCT 2012

Predictors Of Adverse Cardiac Events after PCI With GENOUS EPC-Coated Stents Compared To Drug Eluting Stents

Presenter: Boris Rudenko, Anatoly Savchenko, Serdgey Tereshchenko, Olga Cherkavskaya

January 03, 2012

Advertisement

New Results from SYNTAX, SPIRIT Trials Presented

Meta-Analyses Show Improved Outcomes with DES vs. BMS

J-DESSERT: A Prospective, Randomized Trial of Paclitaxel-Eluting vs. Sirolimus-Eluting Stents in Patients with and without Diabetes

Final Data on the ICARUS Trial of Covered Stents for Obstructive Iliac Disease

Dedicated Bifurcation Stents: Xience SBA Program Update

Dedicated Bifurcation Stents: STENTYS Program Update

Debate I. Are Drug-Eluting Stents Now the Default Strategy for SFA Intervention? - Con!

COURAGE, FAME: Revascularization More Effective Than OMT

ACE-CTO: Angiographic Follow-up After Everolimus-eluting Stents in CTO

Use Of Paclitaxel-Eluting Stents Reduces Target Lesion Revascularization for Dialysis Patients.

Two-Year Outcomes of a Propensity-Matched Comparison of the ION and TAXUS Liberté Paclitaxel-Eluting Stents.

Twelve-Month Clinical Efficacy and Safety of Zotarolimus- versus Everolimus-Eluting Stents in a Series of Asian Population

Tissue coverage and neointimal hyperplasia of overlap vs. non-overlap segments in drug-eluting stents 9-13 months after implantation: in vivo-assessment with optical coherence...

The Nine-Month Outcomes of a Polymer-Free Drug-Eluting Stent (YUKON) Compared with Different Polymer Based Drug-Eluting Stents in Real-World Coronary Artery Lesions.

The Impact of XIENCE V® Everolimus-Eluting Coronary Stents on Health Status in COURAGE-Like Patients.

Short-term effects of sirolimus eluting fully bioabsorbable polymeric coronary stents in a porcine model

Safety and Efficacy of the Xience Everolimus Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice.

Safety and Effectiveness of Everolimus-Eluting Stents in 5054 Patients from a Large, Prospective, Real World Study: Two-Year Clinical Outcomes from the XIENCE V® USA Study.

Response of Endothelial Progenitor Cells To Antiproliferative Drugs Currently Used in Drug Eluting Stents

Predictors Of Adverse Cardiac Events after PCI With GENOUS EPC-Coated Stents Compared To Drug Eluting Stents

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content